Case reports and letters were excluded, and 167 articles were ultimately included in the manuscript for review by reviewing the abstract, and full text
J H Festos, B
Oxamate, but not selective targeting of LDH-A, inhibits medulloblastoma cell glycolysis, growth and motility
Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
Another difference is that, unlike clomiphene and anastrazole, HCG does not increase FSH production, although this should not matter clinically in men whose FSH is already elevated
Since then, it has been discontinued by the manufacturer and is not available in the US